Syneron Candela to Introduce New Technologies at the 2016 American Academy of Dermatology (AAD) Annual Meeting

Debuts include the new CO2RE Intima for gynecological and genitourinary indications for vaginal and vulvar health, an additional ultra-short PicoWay laser wavelength for comprehensive tattoo removal and a SubQ Profound applicator for the stimulation of elastin, collagen, hyaluronic acid and the treatment of adipose tissue.

Mar 03, 2016, 09:00 ET from Syneron Medical Ltd.

IRVINE, Calif., March 3, 2016 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS) a global market leader in the aesthetic medical device marketplace, this week will announce three new product launches during the 2016 American Academy of Dermatology (AAD) meeting in Washington, D.C. The launches include the new CO2RE Intima system for gynecological and genitourinary indications, an ultra-short picosecond PicoWay laser wavelength and a Profound SubQ hand piece. With these announcements, Syneron Candela reaffirms its best-in-class product suite that continues to address the needs of the aesthetic and wellness marketplace with energy based technology innovations.

  • CO2RE Intima, a complete laser solution on Syneron Candela's versatile CO2RE® platform, addresses a growing need in the gynecology market for women's intimate wellness. CO2RE Intima is designed to perform gynecological and genitourinary treatments by stimulating healing responses in the vaginal and vulva areas, while also remodeling the tissue fibers in the vaginal and vulva areas. "Our launch of CO2RE Intima provides physicians with additional options when using our CO2RE platform, allowing us to successfully provide wellness solutions to the gynecology market.  We are very pleased with feedback from our early investigators and believe that the CO2RE Intima will provide compelling value to patients and providers," says Shimon Eckhouse, PhD, Co-founder and Chairman of the Board, Syneron-Candela.
  • The Company is launching a third, ultra-short pulse duration 785nm wavelength[1] for PicoWay®, a leading solution for tattoo removal, pigmentation correction and skin irregularities. The new ultra-short wavelength is the first of its kind in the aesthetic market utilizing a titanium sapphire laser for the removal of blue and green inks. The innovative PicoWay laser platform delivers ultra-short pulses of energy (e.g., 300 picoseconds at 785 nm) making treatments shorter and less painful for patients while offering the industry's shortest pulses and highest peak power. The addition of PicoWay's third wavelength completes the PicoWay laser platform, allowing for the comprehensive removal and treatment of all colors of tattoos and skin pigmentation issues.
  • Profound®, the industry's first microneedle based radiofrequency device, is clinically proven to stimulate three important factors for percutaneous treatment of facial wrinkles: elastin, collagen and hyaluronic acid. The Company is launching a new SubQ hand piece for Profound for the treatment of adipose tissue and deeper connective tissue. With the launch of the new SubQ applicator, Profound is the only real-time temperature controlled micro-needling radiofrequency device for the treatment of both shallow and deep skin at the dermal and subcutaneous layers.

"We are very pleased to be able offer such a broad array of technologically sophisticated solutions to our customers and their patients," said Amit Meridor, chief executive officer for Syneron Candela. "Our new launches represent Syneron Candela's ongoing commitment to advancing technology and providing the widest range of solutions to the aesthetic and wellness marketplace."

Visit the Syneron Candela booth (booth #2421) at the AAD to learn more.

About Syneron Candela

Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, Profound and elōs Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contacts:
Corporate Contact
pr@syneron.com

Media Contact
Lindsay LeCain
617.986.5706
Lindsay_LeCain@lpp.com

[1] 785nm wavelength is the subject of a pending FDA 510(k) notification.

Logo - http://photos.prnewswire.com/prnh/20120528/535447

SOURCE Syneron Medical Ltd.



RELATED LINKS

http://www.syneron-candela.com